BR112022015996A2 - Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 - Google Patents

Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23

Info

Publication number
BR112022015996A2
BR112022015996A2 BR112022015996A BR112022015996A BR112022015996A2 BR 112022015996 A2 BR112022015996 A2 BR 112022015996A2 BR 112022015996 A BR112022015996 A BR 112022015996A BR 112022015996 A BR112022015996 A BR 112022015996A BR 112022015996 A2 BR112022015996 A2 BR 112022015996A2
Authority
BR
Brazil
Prior art keywords
ulcerative colitis
antibody
safe
effective method
treat ulcerative
Prior art date
Application number
BR112022015996A
Other languages
English (en)
Portuguese (pt)
Inventor
Johanns Jewel
Li Katherine
Marano Colleen
Strauss Richard
Zhang Hongyan
O'brien Christopher
Adedokun Omoniyi
Shields-Tuttle Kimberly
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112022015996A2 publication Critical patent/BR112022015996A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022015996A 2020-02-14 2021-02-12 Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 BR112022015996A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976582P 2020-02-14 2020-02-14
PCT/IB2021/051215 WO2021161270A2 (en) 2020-02-14 2021-02-12 Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody

Publications (1)

Publication Number Publication Date
BR112022015996A2 true BR112022015996A2 (pt) 2022-10-11

Family

ID=77271772

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015996A BR112022015996A2 (pt) 2020-02-14 2021-02-12 Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23

Country Status (11)

Country Link
US (2) US20210253690A1 (enExample)
EP (1) EP4103606A4 (enExample)
JP (2) JP2023514567A (enExample)
KR (1) KR20220141847A (enExample)
CN (1) CN115427444A (enExample)
AU (1) AU2021218265A1 (enExample)
BR (1) BR112022015996A2 (enExample)
CA (1) CA3170677A1 (enExample)
IL (1) IL295545A (enExample)
MX (1) MX2022009987A (enExample)
WO (1) WO2021161270A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024151320A2 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
US20170211876A1 (en) * 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
MX2018003376A (es) * 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
TWI744617B (zh) * 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法

Also Published As

Publication number Publication date
EP4103606A2 (en) 2022-12-21
CA3170677A1 (en) 2021-08-19
CN115427444A (zh) 2022-12-02
WO2021161270A2 (en) 2021-08-19
IL295545A (en) 2022-10-01
KR20220141847A (ko) 2022-10-20
EP4103606A4 (en) 2024-04-10
WO2021161270A3 (en) 2021-09-16
JP2023514567A (ja) 2023-04-06
MX2022009987A (es) 2022-11-10
WO2021161270A9 (en) 2022-03-24
JP2026097829A (ja) 2026-06-16
US20240002494A1 (en) 2024-01-04
AU2021218265A1 (en) 2022-10-06
US20210253690A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
DK202300038Y9 (da) Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
EP4233861A3 (en) Compositions for treatment of essential tremor
EP4487908A3 (en) Methods of treating crohn's disease and ulcerative colitis
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
BR112012022801A2 (pt) métodos de diagnosticar e tratar câncer em pacientes que têm ou que desenvolvem resistência a uma primeira terapia contra o câncer.
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BR112016016525A2 (pt) Método para indução de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ em um indivíduo, método para melhorar uma condição em um indivíduo, e método para a produção de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+
BR112022025229A2 (pt) Terapias de anticorpos para infecção por sars-cov-2
BR112023013444A2 (pt) Métodos para tratar doença de crohn e colite ulcerativa
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
WO2021161270A9 (en) Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
BR112017025189A2 (en) composition and uses thereof
WO2015100448A3 (en) Multimodal antimicrobial therapy
MX2023004034A (es) Métodos de tratamiento de la dermatomiositis.
BR112022007314A2 (pt) Método seguro e eficaz de tratamento de colite ulcerativa com anticorpos anti-il12/il23
WO2017189906A8 (en) Immune-based treatment of kras-variant cancer patients
EP4480540A3 (en) A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections
Doobaree et al. The United Kingdom immune thrombocytopenia (UK-ITP) registry: preliminary findings on bleeding events experienced by its participants
BR112023020732A2 (pt) Vetor lentiviral para o tratamento da hepatite b, método e preparação de partículas lentivirais para o tratamento da mesma e composição farmacêutica para o tratamento e/ou prevenção da infecção pelo vírus da hepatite b
NO20081415L (no) Fremgangsmate for utforelse av en perkutan koronar intervensjon
MX2024002584A (es) Tratamientos para la dermatitis atopica.
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]